

## Liverpool John Moores University

Title: CLINICAL AND EXPERIMENTAL PHARMACOLOGY  
Status: Definitive  
Code: **7000SBPHAR** (113116)  
Version Start Date: 01-08-2012

Owning School/Faculty: Pharmacy & Biomolecular Sciences  
Teaching School/Faculty: Pharmacy & Biomolecular Sciences

Team	Leader
Andrew Evans	Y
Neil Henney	
Peter Penson	
Vicki Anderson	
James Downing	
Elsie Gaskell	

**Academic Level:** FHEQ7      **Credit Value:** 10.00      **Total Delivered Hours:** 26.00

**Total Learning Hours:** 100      **Private Study:** 74

### Delivery Options

Course typically offered: Semester 1

Component	Contact Hours
Lecture	18.000
Tutorial	6.000

**Grading Basis:** 40 %

### Assessment Details

Category	Short Description	Description	Weighting (%)	Exam Duration
Exam	AS1	Examination (3 questions out of 4)	100.0	2.00

### Aims

*To study and evaluate current developments on both clinical and experimental pharmacology.*

## Learning Outcomes

After completing the module the student should be able to:

- 1 Demonstrate significant knowledge of those highly specialised aspects of pharmacology which have been selected by contributors to the module for presentation in that year.
- 2 Demonstrate the ability to critically analyse and to evaluate original papers on each selected specialised topics
- 3 Utilise the above skills both for specific topics and as transferable skills for future evaluation of pharmaceutical literature.

## Learning Outcomes of Assessments

The assessment item list is assessed via the learning outcomes listed:

EXAM	1	2	3
------	---	---	---

## Outline Syllabus

*This will change from year to year as a reflection of changes in topicality. Those topics which were selected in 2008/2009 were:*

*Neural control of immune function*

*Life-style related diseases: Animal models of the influence of diet and exercise on cardiovascular risk factors*

*Myocardial ischaemia/reperfusion injury*

*Exploitation of tumour hypoxia for novel anticancer strategies, hypoxia-regulated chemotherapy and gene therapy, role of radiotherapy in cancer treatment*

*Different therapeutics available for cystic fibrosis and the current research into new treatments.*

## Learning Activities

Primary presentation of material will be lecture, provision of key references and direction towards recommended Web sites and further references. Tutorials will be the forum for smaller group discussion, analysis and critical appraisal of information presented to, and acquired by students.

## References

<b>Course Material</b>	Book
<b>Author</b>	
<b>Publishing Year</b>	0
<b>Title</b>	
<b>Subtitle</b>	This will change from year to year as a reflection of changes in topicality. Those topics which were selected in 2008/2009 were:
<b>Edition</b>	
<b>Publisher</b>	
<b>ISBN</b>	

<b>Course Material</b>	Book
<b>Author</b>	Semenza, G.
<b>Publishing Year</b>	2007
<b>Title</b>	Evaluation of HIF-1 inhibitors as anticancer agents.
<b>Subtitle</b>	Drug Discovery Today, 12, 853-859.
<b>Edition</b>	
<b>Publisher</b>	
<b>ISBN</b>	

<b>Course Material</b>	Book
<b>Author</b>	Erler, J. T. & Giaccia, A. J.
<b>Publishing Year</b>	2006
<b>Title</b>	Lysyl oxidase mediates hypoxic control of metastasis.
<b>Subtitle</b>	Cancer Res., 66, 10238-10241.
<b>Edition</b>	
<b>Publisher</b>	
<b>ISBN</b>	

<b>Course Material</b>	Book
<b>Author</b>	McKeown, S. R., Cowen, R. L. & Williams, K. J.
<b>Publishing Year</b>	2007
<b>Title</b>	drugs: from concept to clinic.
<b>Subtitle</b>	Clin. Oncol., 19, 427-442.
<b>Edition</b>	
<b>Publisher</b>	
<b>ISBN</b>	

<b>Course Material</b>	Book
<b>Author</b>	Ziello, J. E., Jovin, I. S., and Huang, Y.
<b>Publishing Year</b>	2007
<b>Title</b>	Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia.
<b>Subtitle</b>	Yale J. Biol. & Med., 80, 51-60.
<b>Edition</b>	

<b>Publisher</b>	
<b>ISBN</b>	

---

### **Notes**

The module will address current trends and/or controversies in clinical and experimental pharmacology.